AsthmaPhase 1RATENCT02401074
Airway Temperature
A Phase 1 study testing Segmental Bronchoprovocation with Allergen (SBP-Ag) in people with Asthma, run by Lu Yuan Lee at 1 site in United States.
Trial summary
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Asthma
- What is being tested?
- Segmental Bronchoprovocation with Allergen (SBP-Ag)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Nov 2018to Jun 2020
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- 18-60 years of age
- Diagnosis of well-controlled airway allergy with mild-intermittent asthma (a stable clinical condition with good asthma control) and demonstrating an allergen-specific airway response to inhaled allergen provocation.
- Pre-albuterol forced expiratory volume in the first second (FEV1) of >70% of the predicted value.
- Skin test positive to house dust mite, ragweed or cat hair.
- At least a 20% decrease in FEV1 during the immediate response following inhaled antigen challenge.
- Competent to understand and willing to grant written informed consent.
Who cannot join
- Inability to perform pulmonary function testing.
- History of any lung disease or disorder other than asthma.
- Major health problems such as autoimmune disease, heart disease, coronary artery disease, type I or type II diabetes, or uncontrolled hypertension.
- Pre-existing chronic infectious disease.
- Medication that is taken for other than for asthma, allergies or contraception.
- Inhaled corticosteroids or oral corticosteroids within 1 month of screening.
Show all 13Show fewer
- Upper and lower respiratory infection within 1 month of screening.
- Unstable asthma as indicated by self report of increased symptoms or increased beta-agonist use over the 2 weeks preceding the screening visit.
- Pregnant or lactating females.
- History of smoking.
- History of noncompliance with medical regiments or subjects who are considered unreliable.
- Use of anti-platelet (i.e., aspirin, clopidogrel, etc) or anti-coagulant(coumadin, heparin, Xarelto®, etc) medication 5 days prior to bronchoscopy.
- It is required that the subjects undergoing bronchoscopy are not on any anti-platelets (such as aspirin, clopidogrel, etc.) or anticoagulants (such as coumadin, heparin, Xarelto®, etc.) at least 5 days prior to the bronchoscopy. As such, subjects receiving any of these medications will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Kentucky Medical Center, Center for Clinical and Translational Science
Lexington, Kentucky, 40536
About this study
Official title: Role of Airway Tissue Temperature in Asthma Exacerbation
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation. The results of this study will bring a better understanding of the potential involvement of an increase in airway mucosa temperature in the pathogenesis of various symptoms in these patients. The finding should help to advance the development of new therapeutic strategies for these debilitating diseases.
Read the detailed description
A total of eight participants will be enrolled into this study. We will take direct measurements of bronchial mucosa temperature. This can only be tested accurately in asthma participants because anesthesia is known to lower the body temperature. The proposed study using and experimental procedure called a segmental bronchoprovocation challenge with allergen in asthmatic patients offers a unique approach to test our hypothesis.
Individuals enrolled into this study will participate for eight weeks and will take part in four visits each estimated to last 2 and 8 hours. Participants will also participant in one follow-up phone call following Test day 2.
Patients with asthma and healthy participants will be recruited to participate in this study through advertisement postings in the Kentucky Clinic and/or the University of Kentucky Hospital as well as on main campus. The study will also be added to a website using the same posting.
Patients with asthma who have been prescribed for a diagnostic or therapeutic bronchoscopy procedure at the UK Pulmonary Clinic will be identified and recruited by qualified physicians in that clinic. The medical history and records of the patients will be made available which includes data form a complete spirometry test and other clinical tests, physical examination, smoking history, symptoms, current medication use, drug allergies, laboratory and imaging data.
After eligible patients are identified and meet proper inclusion criteria, informed consent will be obtained.
Participants will receive an explanation of the research project including any potential risks. In addition, the participant will be shown the actual size of the temperature probe to be used in this procedure. The participation of these individuals in the study will in no way affect their current treatment. No bias will be held against the individual by any clinical staff if they elect not to participate in the study. Informed consent will be obtained after the potential participant is fully informed via verbal/written information of the procedures and nature of the research, the risks involved, and their rights as a research subject.
The experimental procedure will be carried out in the University of Kentucky A.B. Chandler Hospital.
Direct measurements of the airway mucosal temperature will be performed before and at ten minutes after the SBP-Ag challenge. This miniature probe will be positioned in the airway lumen using an Olympus fiberoptic bronchoscope (model MP160F), and connected via a cable to a battery-operated thermometer (model FLL) manufactured also by Physitemp Instrument Inc. The probe (outside diameter of 0.4 mm) will be passed through the instrument channel (inner diameter: 2.0 mm) of the bronchoscope. By maneuvering the control knob of the bronchoscope, the blunted tip of the probe will be gently pressed against the airway mucosa at 5-6 different positions in segmental and sub-segmental bronchi, each for five to ten seconds. The entire protocol of the temperature measurement will require no more than 5 minutes to complete. The contact of the temperature probe on the airway mucosa should not cause any tissue damage, and is relatively non-invasive compared to other procedures involved in the routine bronchoscopy such as biopsy, cytology brushing, etc
Physical Examination: It will include assessment of subject's general condition, head and neck, chest and respiratory auscultation, cardiac auscultation, and limited abdominal, extremity and neurological exams.
Vital signs: Heart rate, blood pressure, body temperature and arterial oxygen saturation.
Screening Visits 1 and 2: Following procedures will occur on the screening visit after obtaining written informed consent.
- Collection of demographic information (Demographic data to be collected on screening visit will include name, initials, address, social security number, coded study number, medical record number, height, weight, age, race, ethnicity, gender, telephone number and email address.)
- Collection of medical and medication history
- Urine pregnancy test
- Vital signs
- Skin prick test
- Spirometry
- Limited physical examination
- Study eligibility review
- Whole lung allergen inhalation challenge
- Adverse Event assessment
- Concomitant medication
Visit 3 (Test Day 1)
- Review eligibility criteria
- Vital signs
- Spirometry
- Urine pregnancy test
- Physical examination
- Bronchoscopy with lavage
- Segmental allergen challenge
- Adverse Event assessment
- Concomitant medication
Visit 4 (Test Day 2)
- Review eligibility criteria
- Vital signs
- Spirometry
- Physical examination
- Bronchoscopy with lavage
- Adverse Event assessment
- Concomitant medication
Follow-up Phone Call. A follow-up phone call will take place 1 day following the last study visit. During this phone call the participant will be asked questions regarding any adverse events they may have experienced since the last visit along with the use of any concomitant medications.
- Conditions
- Asthma
- Being tested
- Segmental Bronchoprovocation with Allergen (SBP-Ag)
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Segmental Bronchoprovocation with Allergen (SBP-Ag)Biological
Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
| Study group | Role | What they receive |
|---|---|---|
| Segmental bronchoprovocation with Allergen (SBP-Ag) | Experimental | Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment. Receives: Biological: Segmental Bronchoprovocation with Allergen (SBP-Ag) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Airway tissue temperature
Direct measurements of the airway mucosal temperature will be performed before and at ten minutes after the SBP-Ag challenge. By maneuvering the control knob of the bronchoscope, the blunted tip of the probe will be gently pressed against the airway mucosa at 5-6 different positions in segmental and sub-segmental bronchi, each for five to ten seconds. The entire protocol of the temperature measurement will require no more than 5 minutes to complete.
Measured: Immediately during experimental procedure (up to 10 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2015 (estimated)
- Study start8 Nov 2018
- Primary completionJun 2020 (estimated)
- Study completionJun 2020 (estimated)
Why it stopped: Study was withdrawn prior to patient enrollment due to COVID-19, funding termination and lack of eligible study participants.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lu Yuan Lee
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Lu Yuan Lee, University of Kentucky
- Investigators
- Lu Yuan Lee, PhD, Principal investigator, University of KentuckyMehdi Khosravi, MD, Principal investigator, University of Kentucky
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02401074
- Sponsor's protocol ID
- IND 16362
- Other IDs
- U01AI123832
- Acronym
- RATE
- Status last verified
- Nov 2020
- First submitted
- 24 Mar 2015
- Last updated
- 9 Dec 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Airway Tissue Temperature in Asthma Exacerbation
- ClinicalTrials.gov ID
- NCT02401074
- Acronym / sponsor ID
- RATE / IND 16362
- Conditions
- Asthma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Study was withdrawn prior to patient enrollment due to COVID-19, funding termination and lack of eligible study participants.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Lu Yuan LeeUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- 8 Nov 2018 (actual)
- Primary completion
- Jun 2020 (estimated)
- Study completion
- Jun 2020 (estimated)
- First posted
- 27 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation. The results of this study will bring a better understanding of the potential involvement of an increase in airway mucosa temperature in the pathogenesis of various symptoms in these patients. The finding should help to advance the development of new therapeutic strategies for these debilitating diseases.
Detailed description
A total of eight participants will be enrolled into this study. We will take direct measurements of bronchial mucosa temperature. This can only be tested accurately in asthma participants because anesthesia is known to lower the body temperature. The proposed study using and experimental procedure called a segmental bronchoprovocation challenge with allergen in asthmatic patients offers a unique approach to test our hypothesis.
Individuals enrolled into this study will participate for eight weeks and will take part in four visits each estimated to last 2 and 8 hours. Participants will also participant in one follow-up phone call following Test day 2.
Patients with asthma and healthy participants will be recruited to participate in this study through advertisement postings in the Kentucky Clinic and/or the University of Kentucky Hospital as well as on main campus. The study will also be added to a website using the same posting.
Patients with asthma who have been prescribed for a diagnostic or therapeutic bronchoscopy procedure at the UK Pulmonary Clinic will be identified and recruited by qualified physicians in that clinic. The medical history and records of the patients will be made available which includes data form a complete spirometry test and other clinical tests, physical examination, smoking history, symptoms, current medication use, drug allergies, laboratory and imaging data.
After eligible patients are identified and meet proper inclusion criteria, informed consent will be obtained.
Participants will receive an explanation of the research project including any potential risks. In addition, the participant will be shown the actual size of the temperature probe to be used in this procedure. The participation of these individuals in the study will in no way affect their current treatment. No bias will be held against the individual by any clinical staff if they elect not to participate in the study. Informed consent will be obtained after the potential participant is fully informed via verbal/written information of the procedures and nature of the research, the risks involved, and their rights as a research subject.
The experimental procedure will be carried out in the University of Kentucky A.B. Chandler Hospital.
Direct measurements of the airway mucosal temperature will be performed before and at ten minutes after the SBP-Ag challenge. This miniature probe will be positioned in the airway lumen using an Olympus fiberoptic bronchoscope (model MP160F), and connected via a cable to a battery-operated thermometer (model FLL) manufactured also by Physitemp Instrument Inc. The probe (outside diameter of 0.4 mm) will be passed through the instrument channel (inner diameter: 2.0 mm) of the bronchoscope. By maneuvering the control knob of the bronchoscope, the blunted tip of the probe will be gently pressed against the airway mucosa at 5-6 different positions in segmental and sub-segmental bronchi, each for five to ten seconds. The entire protocol of the temperature measurement will require no more than 5 minutes to complete. The contact of the temperature probe on the airway mucosa should not cause any tissue damage, and is relatively non-invasive compared to other procedures involved in the routine bronchoscopy such as biopsy, cytology brushing, etc
Physical Examination: It will include assessment of subject's general condition, head and neck, chest and respiratory auscultation, cardiac auscultation, and limited abdominal, extremity and neurological exams.
Vital signs: Heart rate, blood pressure, body temperature and arterial oxygen saturation.
Screening Visits 1 and 2: Following procedures will occur on the screening visit after obtaining written informed consent.
- Collection of demographic information (Demographic data to be collected on screening visit will include name, initials, address, social security number, coded study number, medical record number, height, weight, age, race, ethnicity, gender, telephone number and email address.)
- Collection of medical and medication history
- Urine pregnancy test
- Vital signs
- Skin prick test
- Spirometry
- Limited physical examination
- Study eligibility review
- Whole lung allergen inhalation challenge
- Adverse Event assessment
- Concomitant medication
Visit 3 (Test Day 1)
- Review eligibility criteria
- Vital signs
- Spirometry
- Urine pregnancy test
- Physical examination
- Bronchoscopy with lavage
- Segmental allergen challenge
- Adverse Event assessment
- Concomitant medication
Visit 4 (Test Day 2)
- Review eligibility criteria
- Vital signs
- Spirometry
- Physical examination
- Bronchoscopy with lavage
- Adverse Event assessment
- Concomitant medication
Follow-up Phone Call. A follow-up phone call will take place 1 day following the last study visit. During this phone call the participant will be asked questions regarding any adverse events they may have experienced since the last visit along with the use of any concomitant medications.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Segmental bronchoprovocation with Allergen (SBP-Ag) | Experimental | Biological: Segmental Bronchoprovocation with Allergen (SBP-Ag)Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- 18-60 years of age
- Diagnosis of well-controlled airway allergy with mild-intermittent asthma (a stable clinical condition with good asthma control) and demonstrating an allergen-specific airway response to inhaled allergen provocation.
- Pre-albuterol forced expiratory volume in the first second (FEV1) of >70% of the predicted value.
- Skin test positive to house dust mite, ragweed or cat hair.
- At least a 20% decrease in FEV1 during the immediate response following inhaled antigen challenge.
Key exclusion criteria (13 listed)
- Inability to perform pulmonary function testing.
- History of any lung disease or disorder other than asthma.
- Major health problems such as autoimmune disease, heart disease, coronary artery disease, type I or type II diabetes, or uncontrolled hypertension.
- Pre-existing chronic infectious disease.
- Medication that is taken for other than for asthma, allergies or contraception.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Segmental Bronchoprovocation with Allergen (SBP-Ag)Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5) | Biological | Segmental bronchoprovocation with Allergen (SBP-Ag) |
Primary outcome
Airway tissue temperature
Time frame: Immediately during experimental procedure (up to 10 minutes)
Direct measurements of the airway mucosal temperature will be performed before and at ten minutes after the SBP-Ag challenge. By maneuvering the control knob of the bronchoscope, the blunted tip of the probe will be gently pressed against the airway mucosa at 5-6 different positions in segmental and sub-segmental bronchi, each for five to ten seconds. The entire protocol of the temperature measurement will require no more than 5 minutes to complete.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2020.
- Individual participant dataSharing planned: No
Related trials for Asthma
RecruitingObservational study
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
Asthma
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Active, not recruiting
Community Health Equity Accelerator (CHEA) Pediatric Asthma Intervention
Asthma in Children
RecruitingObservational study
Remote Monitoring of Asthma in Children and Young People
Asthma Childhood, Asthma Attack
RecruitingPhase 3
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lu Yuan Lee, PhD principal investigator
University of Kentucky
Mehdi Khosravi, MD principal investigator
University of Kentucky
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Segmental Bronchoprovocation with Allergen (SBP-Ag) in people with Asthma, run by Lu Yuan Lee at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 9 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Airway tissue temperature (time frame: Immediately during experimental procedure (up to 10 minutes)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2020; AzTrials last refreshed its copy on 28 Oct 2026.